Ruxolitinib

Chemical Properties

Melting point
84-89°C

Density 
1.40

storage temp. 
-20°

solubility 
Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming).

form 
White powder.

pka
11.63±0.50(Predicted)

color 
White

Stability
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.

InChI
InChI=1/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/s3

InChIKey
HFNKQEVNSGCOJV-UJHUVDBMNA-N

SMILES
[C@@H](C1CCCC1)(N1N=CC(C2N=CN=C3NC=CC=23)=C1)CC#N |&1:0,r|

CAS DataBase Reference
941678-49-5

Ruxolitinib is the first oral medication approved by the US Food and Drug Administration (FDA) for the treatment of myelofibrosis. It is a small-molecule inhibitor of the tyrosine kinase (namely, JAK1 and JAK2) and is suitable for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia Vera myelofibrosis and post essential thrombocythemia myelofibrosis.